Literature DB >> 3740128

Serum free carnitine, carnitine esters and lipids in patients on peritoneal dialysis and hemodialysis.

C Wanner, S Förstner-Wanner, G Schaeffer, P Schollmeyer, W H Hörl.   

Abstract

Serum free and esterified carnitine levels as well as lipids were investigated in patients undergoing regular hemodialysis (HD) treatment before and during 12 weeks of treatment with L-carnitine (1 g i.v.) at the end of each HD. The results were compared with those obtained in patients on continuous ambulatory peritoneal dialysis (CAPD; n = 15) or intermittent peritoneal dialysis (IPD; n = 3) and healthy controls (CO; n = 20). In HD patients (n = 23) total carnitine (TC) was 49.9 +/- 3.9 (CO: 46.0 +/- 2.5; NS), free carnitine (FC) was 31.6 +/- 2.8 (CO: 37.4 +/- 1.3; p less than 0.05), short-chain acylcarnitine (SCC) was 17.0 +/- 1.8 (CO: 7.2 +/- 0.9; p less than 0.0001) and long-chain acylcarnitine (LCC) was 1.2 +/- 0.2 mumol/l (CO: 0.6 +/- 0.1; p less than 0.05). FC was in the normal range in CAPD (35.6 +/- 3.2) and IPD (44.5 +/- 8.0 mumol/l) patients, whereas SCC (30.1 +/- 3.5) and LCC (2.9 +/- 0.2) levels were maximal elevated in IPD patients (11.8 +/- 0.8 and 1.5 +/- 0.2 on CAPD). Therefore, TC was higher in IPD than in CAPD patients (77.5 +/- 5.0 vs. 49.0 +/- 3.5 mumol/l). 12 weeks after L-carnitine supplementation in HD patients, TC was 313.9 +/- 22.6, FC was 207.7 +/- 12.4, SCC was 99.6 +/- 12.1 and LCC was 7.1 +/- 0.6 mumol/l. TC and FC were significantly lower in females compared with males. Total cholesterol and ketone bodies were normal, HDL cholesterol was significantly decreased before and after L-carnitine supplementation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3740128     DOI: 10.1159/000167119

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

Review 1.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

2.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

Review 3.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  L-Carnitine status in end-stage renal disease patients on automated peritoneal dialysis.

Authors:  Lorenzo Di Liberato; Arduino Arduini; Claudia Rossi; Augusto Di Castelnuovo; Cosima Posari; Paolo Sacchetta; Andrea Urbani; Mario Bonomini
Journal:  J Nephrol       Date:  2014-03-06       Impact factor: 3.902

5.  Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients.

Authors:  Celalettin Koşan; Lale Sever; Nil Arisoy; Salim Calişkan; Ozgür Kasapçopur
Journal:  Pediatr Nephrol       Date:  2003-10-02       Impact factor: 3.714

6.  Choline catabolism to glycine betaine contributes to Pseudomonas aeruginosa survival during murine lung infection.

Authors:  Matthew J Wargo
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

Review 7.  Current Opinion on Usage of L-Carnitine in End-Stage Renal Disease Patients on Peritoneal Dialysis.

Authors:  Mario Bonomini; Lorenzo Di Liberato; Victor Zammit; Arduino Arduini
Journal:  Molecules       Date:  2019-09-23       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.